We know when the cult say “oh, I’m not sure if this has been posted before” it has.
I’m not sure that the stat of science, and indeed, things such as different Covid mutations hasn’t advanced since February 2021. I think things have moved on? From when wilb’s article was published.
But I do know that MSBs stem development hasn’t. Still hasn’t fixed the quality control problems.
Still not allowed to conduct needed trials.
Not sure why msb thinks the Covid application is still still still a “focus”. It’s dead as the Novartis partnership. Maybe it says more about the other applications?
Growing doubt on COVID-19 Application, page-2607
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
-0.010(0.69%) |
Mkt cap ! $1.644B | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.43 | $4.048M | 2.778M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26808 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 16001 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |